Celularity Inc (CELU)
Celularity Inc. is a healthcare company focused on regenerative and cellular medicines aimed at aging-related and degenerative diseases. The company develops placental-derived, allogeneic cell therapy candidates designed for off-the-shelf use, including programs under Cell Therapy and Degenerative Disease such as PDA-001 for Crohn’s disease and other autoimmune or degenerative conditions, PDA-002 for facioscapulohumeral muscular dystrophy, and pExo-001 for osteoarthritis. Through its BioBanking segment, Celularity also collects, processes, and stores umbilical cord and placental blood and tissue under the LifebankUSA brand. In addition, it produces and licenses products used in surgical and wound care markets, including Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex. The company was founded in 1998 and is headquartered in Florham Park, New Jersey.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CELU
|
$1.04
|
33.2% Upside
|
Undervalued
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-0.2x
|
-0.6x
|
0.9x
|
22.578 M
|
91.445 M
|
76.6%
|
65.2%
|
-17.7
|
—
|
14.5%
|
